Deerfield
About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More
---
Investment

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More
---
Information

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---
Philanthropy

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
---
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
---
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
---
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
---
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
---
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

Deerfield Continues its Commitment to Advancing Healthcare Through its Publication Activities

New York, NY – January 16, 2018 – For the third year in a row, Deerfield has fulfilled its commitment to research in healthcare through the publication of articles, reviews and abstracts, which total over 40 since 2015. In addition, Deerfield has set up strategic collaborations with renowned organizations such as Friends Of Cancer Research (FOCR) and the Peking Union School of Public Health (PUSPH). The aim of these collaborations is to jointly publish information that addresses US and China health needs.

The peer‐reviewed publications, reviews and abstracts published in 2017 are listed below:

  1. Consumer satisfaction with tertiary healthcare in China: findings from the 2015 China National patient survey. Sun J, Hu G, Ma J, Chen Y, Wu L, Liu Q, Hu J, Livoti C, Jiang Y, Liu Y. Int J Qual Heath Care, 2017; 29(2):213‐221
  2. Considerations on Bringing Warehoused HCV Patients into Active Care Following Interferon‐Free, Direct‐Acting Antiviral Drug Approval. Palak A, Livoti C, Audibert C. Postgrad Med, 2017;129(4):471‐475
  3. Investment and incentives in 21st Century pharmaceutical research in Europe: the cost of opportunity. Morgese P. The European File, March 2017.
    https://www.europeanfiles.eu/magazine/medicines‐future‐how‐to‐sustain‐pharmaceuticalinnovation‐and‐improve‐access‐and‐affordability
  4. Global perspective on colonoscopy use for colorectal cancer screening: a multi‐country survey of practicing colonoscopists. Audibert C, Perlaky A, Glass D. Contemporary Clinical Trials Communications volume 7, September 2017, pages 116‐121.
  5. Reducing waiting time and raising outpatient satisfaction in a Chinese public tertiary general hospital – an interrupted time series study. Sun J, Lin Q, Zhao P, Zhang Q, Xu K, Chen H, Hu C, Stuntz M, Li H, Liu Y. Lancet ‐ CASM conference Abstract, and BMC Public Health, 2017;17:668
  6. Trends in the molecular diagnosis of lung cancer, results from an online marker research survey. Audibert C, Shea MB, Glass DJ, Kozak ML, Cazé A, Hohman RM, Allen JD, Sigal EV, Leff JS. A Friends Of Cancer Research White Paper, July 2017.
    https://www.focr.org/sites/default/files/pdf/FINAL%202017%20Friends%20NSCLC%20White%20Paper.pdf
  7. Nationwide trends of clinical characteristics and economic burden of emergency department visits due to acute ischemic stroke. Stuntz M, Busko K, Irshad S, Paige T, Razhkova V, Coan T. Open Access Emerg Med, 2017 Sep 19;9:89‐96
  8. Is it time for the weighted log‐rank test to play a more important role in confirmatory trials? SuZ, Zhu M. Contemporary Clinical Trials Communications, September 17, 2017.
  9. Variability in the therapeutic management of advanced ovarian cancer patients: a 5‐country survey of oncologists. Audibert C, Perlaky A, Stuntz M, Glass D. Drug Des Dev Ther, 2017;.11:3471‐3479.
  10. Treatment sequencing in advanced BRAF‐mutant melanoma patients: current practice in the United States. Audibert C, Stuntz M, Glass D. Journal of Pharmacy Technology, 2017 published online December 4.
  11. Persisting disparities between sexes in outcomes of ruptured abdominal aortic aneurysm hospitalizations. Stuntz M, Audibert C, Su Z. Scientific Reports, 2017; 10.1038/s41598‐017‐18451‐2 (SREP‐17‐46111)
  12. A review of promoting access to medicines in China – problems and recommendations. Sun J, HuC, Stuntz M, Hogerzeil H, Liu Y. Accepted by BMC Health Services Research.

About Deerfield

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.

For more information, please visit www.deerfield.com.

Contacts

Deerfield Management Company
Karen Heidelberger, 212-551-1600
[email protected]